Atea Pharmaceuticals (AVIR) Competitors $3.21 +0.04 (+1.26%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. WVE, NAGE, MLYS, RCUS, SYRE, AKBA, CVAC, ELVN, PAHC, and COLLShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), CureVac (CVAC), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics CureVac Enliven Therapeutics Phibro Animal Health Collegium Pharmaceutical Wave Life Sciences (NASDAQ:WVE) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Does the media prefer WVE or AVIR? In the previous week, Wave Life Sciences had 10 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Wave Life Sciences and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Wave Life Sciences' score of 1.11 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Wave Life Sciences Positive Atea Pharmaceuticals Very Positive Do analysts prefer WVE or AVIR? Wave Life Sciences currently has a consensus target price of $20.50, indicating a potential upside of 184.72%. Atea Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 86.92%. Given Wave Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Wave Life Sciences is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community favor WVE or AVIR? Wave Life Sciences received 350 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 67.83% of users gave Wave Life Sciences an outperform vote while only 46.34% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformWave Life SciencesOutperform Votes36967.83% Underperform Votes17532.17% Atea PharmaceuticalsOutperform Votes1946.34% Underperform Votes2253.66% Which has stronger valuation & earnings, WVE or AVIR? Wave Life Sciences has higher revenue and earnings than Atea Pharmaceuticals. Wave Life Sciences is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWave Life Sciences$104.94M10.58-$57.51M-$0.84-8.57Atea PharmaceuticalsN/AN/A-$135.96M-$1.65-1.95 Do insiders & institutionals have more ownership in WVE or AVIR? 89.7% of Wave Life Sciences shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 29.1% of Wave Life Sciences shares are held by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is WVE or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Atea Pharmaceuticals' return on equity of -34.90% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Wave Life Sciences-66.50% -280.57% -52.90% Atea Pharmaceuticals N/A -34.90%-32.38% Which has more volatility & risk, WVE or AVIR? Wave Life Sciences has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. SummaryWave Life Sciences beats Atea Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$274.71M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-1.558.7927.2619.97Price / SalesN/A263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book0.486.597.064.69Net Income-$135.96M$144.20M$3.24B$248.14M7 Day Performance0.63%3.81%2.56%2.39%1 Month Performance8.45%11.10%8.75%6.06%1 Year Performance-15.08%3.95%31.30%13.57% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals3.3763 of 5 stars$3.21+1.3%$6.00+86.9%-19.1%$274.71MN/A-1.5570Positive NewsWVEWave Life Sciences4.4435 of 5 stars$7.05-2.4%$21.17+200.2%+16.0%$1.09B$104.94M-6.35240News CoveragePositive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4834 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120News CoverageAnalyst ForecastMLYSMineralys Therapeutics3.0564 of 5 stars$16.19+0.4%$38.00+134.7%+19.7%$1.06BN/A-4.4528Positive NewsAnalyst ForecastRCUSArcus Biosciences2.5509 of 5 stars$9.86-1.1%$24.13+144.7%-41.9%$1.04B$141M-3.13500Options VolumeAnalyst RevisionGap UpSYRESpyre Therapeutics2.4 of 5 stars$17.16+1.1%$53.40+211.2%-52.6%$1.03B$890K-2.3073Positive NewsAKBAAkebia Therapeutics4.4659 of 5 stars$3.83-3.5%$6.75+76.2%+221.6%$1.01B$184.91M-16.65430News CoverageHigh Trading VolumeCVACCureVac4.4809 of 5 stars$4.48+1.6%$11.00+145.5%-4.2%$1.01B$523.70M8.15880Trending NewsOptions VolumeGap UpELVNEnliven Therapeutics2.4871 of 5 stars$20.34-1.9%$37.25+83.1%-10.9%$998.06MN/A-10.7150Insider TradePAHCPhibro Animal Health3.8792 of 5 stars$24.23+0.6%$20.00-17.5%+45.6%$982.14M$1.19B50.481,860Positive NewsCOLLCollegium Pharmaceutical4.0318 of 5 stars$30.44+0.8%$43.75+43.7%-8.8%$978.10M$664.28M13.12210Positive NewsInsider Trade Related Companies and Tools Related Companies Wave Life Sciences Alternatives Niagen Bioscience Alternatives Mineralys Therapeutics Alternatives Arcus Biosciences Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives CureVac Alternatives Enliven Therapeutics Alternatives Phibro Animal Health Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVIR Stock Free AVIR Stock Alerts